Prognostic value of postsurgical stimulated thyroglobulin levels after initial radioactive iodine therapy in well-differentiated thyroid carcinoma

Head and Neck

Volumn 30, Issue 6, 2008, Pages 693-700

  Sawka, Anna M ^a   Orlov, Steven ^b   Gelberg, Jacob ^b   Stork, Barry ^b   Dowar, Mark ^b   Shaytzag, Michael ^b   Tabatabaie, Vafa ^b   Freeman, Jeremy L ^b   Walfish, Paul G ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical predictors; Iodine radioisotopes; Prognosis; regression analysis; Thyroglobulin; Thyroid carcinoma; TNM pathologic stage

Indexed keywords

LEVOTHYROXINE; LIOTHYRONINE; RADIOACTIVE IODINE; THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ADOLESCENT; ADULT; AGED; CARCINOMA; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 46249104325     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20755     Document Type: Article

References (32)

1. Ahmedin J, Taylor M, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States. JAMA 2006;295:2164-2167.
3. Park SH, Suh EH, Chi JG. A histopathologic study on 1,095 surgically resected thyroid specimens. Jpn J Clin Oncol 1988;18:297-302.
4. Parkin M, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2002;55:74-108.
5. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. A systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3668-3676.
6. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 1997;79:2414-2423.
7. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-142.
8. Van Herle AJ, Uller RP. Elevated serum thyroglobulin: a marker of metastases in differentiated thyroid carcinomas. J Clin Invest 1975;56:272-277.
9. Black EG, Cassoni A, Gimlettte TM, et al. Serum thyroglobulin in thyroid cancer. Lancet 1981;2:443-455.
10. Blahd WH, Drickman MV, Porter CW, Hill VA, Baum-gartner WA. Serum thyroglobulin, a monitor of differentiated thyroid carcinoma in patients receiving thyroid hormone suppression therapy: concise communication. J Nucl Med 1984;25:673-676.
11. Eustatia-Rutten CFA, Smit JWA, Romijin JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61: 61-74.
12. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-112.
13. Spencer CA, Bergoglio LM, Kazarosyan M, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg antibody method differences in the management of patients with well-differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566-5575.
14. Rosario PWS, Guimaraes VC, Maia FFR, et al. Thyroglobulin before ablation and correlation with posttreatment scanning. Laryngoscope 2007;115:264-267.
15. Grunwald F, Menzel C, Fimmers R, Zamora PO, Biersack HJ. Prognostic value of thyroglobulin after thyroid-ectomy before ablative radioiodine therapy in thyroid cancer. J Nucl Med 1996;37:1962-1964.
16. Hall FT, Beasley NJ, Eski SJ, Witterick IJ, Walfish PG, Freeman JL. Predictive value of serum thyroglobulin after surgery for thyroid carcinoma. Laryngoscope 2003; 113:77-81.
17. Toubeau M, Touzery C, Arveux P, et al. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after 1311 ablation therapy in patients with differentiated thyroid cancer. J Nucl Med 2004;45:988-994.
18. Bernier MO, Morel O, Rodien P, et al. Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imag 2005;32:1418-1421.
19. Giovanella L, Ceriani L, Ghelfo A, Keller F. Thyroglobulin assay 4 weeks after thyroidectomy predicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med 2005;43:843-847.
20. Kim TY, Kim WB, Kim ES, et al. Serum thyroglobulin levels at the time of 1311 remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005;90: 1440-1445.
21. Heemstra KA, Liu YY, Stokkel M, et al. Serum thyroglo-bulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2007;66:58-64.
22. Golger A, Fridman TR, Eski S, Witterick IJ, Freeman JL, Walfish PG. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma. J Endocrinol Invest 2003;26:1023-1031.
23. American Joint Committee on Cancer (AJCC). AJCC cancer staging manual, 6th ed. New York: Springer-Verlag; 2002.
24. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-424.
25. Agresti A. Logistic regression. In: Agresti A, editor. An introduction to categorical data analysis. New York: Wiley; 1996. pp 103-144.
26. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997;16:965-980.
27. Altman DG, Machin D, Bryant TN, Gardner M. Statistics with confidence, 2nd ed. London, UK: British Medical Journal; 2000.
28. Harrell FE Jr, Lee KL, Matchar DB, Reichert TA. Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep 1985;69:1071-1077.
29. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:1373-1379.
30. Leboulleaux S, Rubino C, Baudin E, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab 2005;90:5723-5729.
31. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 1311 whole body scan: comparison of patients treated with high 1311 activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092-4097.
32. Baudin E, Do Cao C, Cailleux AF, Leboulleaux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003;88: 1107-1111.